Liothyronine Sodium Tablets Recalled for Failed Impurity Specifications
Sun Pharmaceutical is recalling approximately 2,304 bottles of Liothyronine Sodium Tablets, USP, 25 mcg (lot DNC2204A) due to failed impurity and degradation specifications. The affected medication was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a prescription medication due to failed impurity and degradation specifications. No illnesses or injuries have been reported. The hazard represents a risk-of-harm product where quality standards were not met, fitting the High severity category per the rubric.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling Liothyronine Sodium Tablets, USP, 25 mcg from lot DNC2204A (expiration date 11/2023) due to failed impurities and degradation specifications. Approximately 2,304 bottles of the medication were affected by this recall.
Liothyronine Sodium is a prescription medication used to treat thyroid conditions. The recall was initiated because the affected lot failed to meet established quality standards for impurities and degradation, meaning the medication may not perform as intended or could contain unintended substances.
The affected medication was distributed nationwide within the United States. Patients taking Liothyronine Sodium should verify the lot number (DNC2204A) and expiration date on their medication. Anyone with the affected lot should contact their healthcare provider or pharmacist for guidance before continuing use.
The recalled product
- Product
- LIOTHYRONINE SODIUM (LIOTHYRONINE SODIUM)
- Brand
- LIOTHYRONINE SODIUM
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Hazard
- Affected units
- 2,304
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: DNC2204A
- Exp. Date 11/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by SUN PHARMACEUTICAL INDUSTRIES INC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · LIOTHYRONINE SODIUM
- ModerateLiothyronine Sodium tablets recalled due to failed impurity and degradation specifications
FDA (Drugs) · 2023-12-20
- HighLiothyronine Sodium Tablets Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2023-11-08
- ModerateSigmaPharm Recalls Liothyronine Sodium Tablets Due to Cross-Contamination
FDA (Drugs) · 2014-05-28
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17